{"id":2816,"date":"2024-06-26T16:26:06","date_gmt":"2024-06-26T08:26:06","guid":{"rendered":"https:\/\/dianhuaminglu.com\/?p=2816"},"modified":"2024-06-26T16:27:05","modified_gmt":"2024-06-26T08:27:05","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c%e9%80%82%e5%ba%94%e7%97%87%e5%9c%a8","status":"publish","type":"post","link":"https:\/\/dianhuaminglu.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c%e9%80%82%e5%ba%94%e7%97%87%e5%9c%a8\/","title":{"rendered":"\u541b\u5b9e\u751f\u7269\u5ba3\u5e03\u7279\u745e\u666e\u5229\u5355\u6297\u4e09\u9634\u6027\u4e73\u817a\u764c\u9002\u5e94\u75c7\u5728\u4e2d\u56fd\u83b7\u6279"},"content":{"rendered":"\n
\u5317\u4eac\u65f6\u95f42024\u5e746\u670825\u65e5\uff0c\u541b\u5b9e\u751f\u7269\uff081877.HK\uff0c688180.SH\uff09\u5ba3\u5e03\uff0c\u7531\u516c\u53f8\u81ea\u4e3b\u7814\u53d1\u7684\u6297PD-1\u5355\u6297\u836f\u7269\u7279\u745e\u666e\u5229\u5355\u6297\u6ce8\u5c04\u6db2\uff08\u62d3\u76ca\u00ae<\/sup>\uff09\u8054\u5408\u6ce8\u5c04\u7528\u7d2b\u6749\u9187\uff08\u767d\u86cb\u767d\u7ed3\u5408\u578b\uff09\u7528\u4e8e\u7ecf\u5145\u5206\u9a8c\u8bc1\u7684\u68c0\u6d4b\u8bc4\u4f30PD-L1\u9633\u6027\uff08CPS\u22651\uff09\u7684\u590d\u53d1\u6216\u8f6c\u79fb\u6027\u4e09\u9634\u6027\u4e73\u817a\u764c\uff08TNBC\uff09\u7684\u4e00\u7ebf\u6cbb\u7597\u65b0\u9002\u5e94\u75c7\u4e0a\u5e02\u7533\u8bf7\u4e8e\u8fd1\u65e5\u83b7\u5f97\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\u3002\u8fd9\u662f\u7279\u745e\u666e\u5229\u5355\u6297\u5728\u4e2d\u56fd\u5185\u5730\u83b7\u6279\u7684\u7b2c\u5341\u9879\u9002\u5e94\u75c7\u3002<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n
\u636e\u7edf\u8ba1\uff0c\u5168\u7403\u4e73\u817a\u764c\u7684\u5e74\u65b0\u53d1\u75c5\u4f8b\u6570\u8fbe231\u4e07\uff0c\u6b7b\u4ea1\u75c5\u4f8b\u6570\u8fbe67\u4e07[1]<\/sup>\uff0c\u662f\u5168\u7403\u5973\u6027\u53d1\u75c5\u7387\u6700\u9ad8\u7684\u764c\u75c7\u3002\u5728\u6211\u56fd\uff0c\u4e73\u817a\u764c\u5e74\u65b0\u53d1\u75c5\u4f8b\u6570\u8fbe35.7\u4e07\uff0c\u6b7b\u4ea1\u75c5\u4f8b\u6570\u8fbe7.5\u4e07\uff0c\u5206\u522b\u5360\u5168\u7403\u75c5\u4f8b\u6570\u768415.5%\u548c11.2%[2]<\/sup>\u3002\u5176\u4e2d\uff0c\u4e09\u9634\u6027\u4e73\u817a\u764c\uff08TNBC\uff09\u7ea6\u5360\u6240\u6709\u4e73\u817a\u764c\u768410-15%\uff0c\u5177\u6709\u4fb5\u88ad\u6027\u5f3a\u3001\u590d\u53d1\u7387\u9ad8\u548c\u9884\u540e\u8f83\u5dee\u7684\u7279\u70b9[3]<\/sup>\u3002\u665a\u671fTNBC\u5bf9\u9776\u5411\u6cbb\u7597\u548c\u5185\u5206\u6ccc\u6cbb\u7597\u4e0d\u654f\u611f\uff0c\u7f3a\u4e4f\u7279\u5f02\u6027\u7684\u6cbb\u7597\u65b9\u6cd5\u3002\u4e2d\u56fd\u76ee\u524d\u7684TNBC\u6cbb\u7597\u4ecd\u4ee5\u5316\u7597\u4e3a\u4e3b\uff0c\u4f46\u65e0\u8bba\u5355\u836f\u6216\u662f\u8054\u5408\u5316\u7597\u5747\u7597\u6548\u6b20\u4f73\uff0c\u4e2d\u4f4d\u751f\u5b58\u671f\u7ea69~12\u4e2a\u6708\uff0c5\u5e74\u751f\u5b58\u7387\u4e0d\u8db330%[4,5]<\/sup>\u3002<\/p>\n\n\n\n
\u672c\u6b21\u65b0\u9002\u5e94\u75c7\u7684\u83b7\u6279\u4e3b\u8981\u57fa\u4e8eTORCHLIGHT\u7814\u7a76\uff08NCT04085276\uff09\u7684\u6570\u636e\u7ed3\u679c\u3002TORCHLIGHT\u7814\u7a76\u662f\u4e00\u9879\u968f\u673a\u3001\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5bf9\u7167\u3001\u591a\u4e2d\u5fc3\u7684III\u671f\u4e34\u5e8a\u7814\u7a76\uff0c\u7531\u4e2d\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08CSCO\uff09\u526f\u7406\u4e8b\u957f\u517c\u79d8\u4e66\u957f\u3001\u89e3\u653e\u519b\u603b\u533b\u9662\u80bf\u7624\u533b\u5b66\u90e8\u6c5f\u6cfd\u98de\u6559\u6388<\/strong>\u62c5\u4efb\u4e3b\u8981\u7814\u7a76\u8005\uff0c\u5728\u5168\u56fd56\u5bb6\u4e2d\u5fc3\u8054\u5408\u5f00\u5c55\u3002<\/p>\n\n\n\n
2023\u5e742\u6708\uff0c\u72ec\u7acb\u6570\u636e\u76d1\u67e5\u59d4\u5458\u4f1a\uff08IDMC\uff09\u5728\u671f\u4e2d\u5206\u6790\u65f6\u5224\u5b9aTORCHLIGHT\u7814\u7a76\u7684\u4e3b\u8981\u7ec8\u70b9\u8fbe\u5230\u65b9\u6848\u9884\u8bbe\u7684\u4f18\u6548\u754c\u503c\uff0c\u6210\u4e3a\u56fd\u5185\u9996\u4e2a\u5728\u665a\u671fTNBC\u514d\u75ab\u6cbb\u7597\u9886\u57df\u53d6\u5f97\u9633\u6027\u7ed3\u679c\u7684III\u671f\u6ce8\u518c\u7814\u7a76\u3002<\/p>\n\n\n\n
2024\u5e741\u6708\uff0c\u56fd\u9645\u9876\u5c16\u533b\u5b66\u671f\u520a\u300a\u81ea\u7136-\u533b\u5b66\u300b\uff08Nature Medicine<\/em>\uff0c\u5f71\u54cd\u56e0\u5b50\uff1a82.9\uff09\u53d1\u8868\u4e86TORCHLIGHT\u7814\u7a76\u671f\u4e2d\u5206\u6790\u6570\u636e\u3002\u7ed3\u679c\u663e\u793a\uff0c\u4e0e\u6ce8\u5c04\u7528\u7d2b\u6749\u9187\uff08\u767d\u86cb\u767d\u7ed3\u5408\u578b\uff09\u76f8\u6bd4\uff0c\u7279\u745e\u666e\u5229\u5355\u6297\u8054\u5408\u6ce8\u5c04\u7528\u7d2b\u6749\u9187\uff08\u767d\u86cb\u767d\u7ed3\u5408\u578b\uff09\u7528\u4e8e\u9996\u8bcaIV\u671f\u6216\u590d\u53d1\u8f6c\u79fb\u6027TNBC\u60a3\u8005\u53ef\u663e\u8457\u5ef6\u957fPD-L1\u9633\u6027\u4eba\u7fa4\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\uff0c\u603b\u751f\u5b58\u671f\uff08OS\uff09\u4e5f\u8fbe\u5230\u4e86\u83b7\u76ca\u8d8b\u52bf\uff0c\u5b9e\u73b0\u4e86\u4e2d\u56fd\u665a\u671fTNBC\u514d\u75ab\u6cbb\u7597\u96f6\u7684\u7a81\u7834\u3002\u5176\u4e2d\uff0c\u7279\u745e\u666e\u5229\u5355\u6297\u7ec4\u7684\u4e2d\u4f4dPFS\u8fbe8.4\u4e2a\u6708\uff0c\u75be\u75c5\u8fdb\u5c55\u6216\u6b7b\u4ea1\u98ce\u9669\u964d\u4f4e35%\uff08P=0.0102\uff09\uff1b\u7279\u745e\u666e\u5229\u5355\u6297\u7ec4\u7684\u4e2d\u4f4dOS\u5ef6\u957f\u4e8613.3\u4e2a\u6708\uff0832.8\u4e2a\u6708 vs 19.5\u4e2a\u6708\uff09\uff0c\u6b7b\u4ea1\u98ce\u9669\u964d\u4f4e\u4e8638%\uff08P=0.0148\uff09\uff0c\u7279\u745e\u666e\u5229\u5355\u6297\u5b89\u5168\u6027\u6570\u636e\u4e0e\u5df2\u77e5\u98ce\u9669\u76f8\u7b26\uff0c\u672a\u53d1\u73b0\u65b0\u7684\u5b89\u5168\u6027\u4fe1\u53f7\u3002<\/p>\n\n\n\n
\u89e3\u653e\u519b\u603b\u533b\u9662\u80bf\u7624\u533b\u5b66\u90e8\u6c5f\u6cfd\u98de\u6559\u6388<\/strong>\u8868\u793a\uff1a\u201c\u514d\u75ab\u6cbb\u7597\u5df2\u6210\u4e3a\u4e09\u9634\u6027\u4e73\u817a\u764c\u6700\u91cd\u8981\u7684\u6cbb\u7597\u624b\u6bb5\uff0cTORCHLIGHT\u7814\u7a76\u5728\u4f20\u7edf\u5316\u7597\u57fa\u7840\u4e0a\u52a0\u5165\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\uff0c\u4e0d\u4ec5\u663e\u8457\u5ef6\u957f\u665a\u671fTNBC\u60a3\u8005\u7684mPFS\uff0c\u4e14\u663e\u793a\u51fa\u663e\u8457\u7684\u751f\u5b58\u83b7\u76ca\u8d8b\u52bf\uff0c\u63d0\u9ad8TNBC\u60a3\u8005\u603b\u751f\u5b58\u8d8530\u6708\u3002\u7279\u745e\u666e\u5229\u5355\u6297\u4f5c\u4e3a\u56fd\u5185\u9996\u4e2a\u5728TNBC\u9886\u57df\u83b7\u6279\u7684\u514d\u75ab\u7597\u6cd5\uff0c\u5c06\u6210\u4e3aTNBC\u4e00\u7ebf\u6cbb\u7597\u65b0\u6807\u51c6\u3002\u201d<\/p>\n\n\n\n
\u541b\u5b9e\u751f\u7269\u603b\u7ecf\u7406\u517c\u9996\u5e2d\u6267\u884c\u5b98\u90b9\u5efa\u519b\u535a\u58eb<\/strong>\u8868\u793a\uff1a\u201c\u957f\u671f\u4ee5\u6765\uff0c\u665a\u671f\u4e09\u9634\u6027\u4e73\u817a\u764c\u9886\u57df\u4e00\u76f4\u7f3a\u4e4f\u6709\u6548\u7684\u6cbb\u7597\u624b\u6bb5\uff0c\u6b64\u6b21\u65b0\u9002\u5e94\u75c7\u7684\u83b7\u6279\u662f\u6211\u4eec\u53c8\u4e00\u6b21\u6210\u529f\u5c1d\u8bd5\uff0c\u4e3a\u4e2d\u56fd\u665a\u671f\u4e09\u9634\u6027\u4e73\u817a\u764c\u60a3\u8005\u5e26\u6765\u4e86\u65b0\u7684\u5e0c\u671b\u3002\u76ee\u524d\uff0c\u9664\u4e86\u7279\u745e\u666e\u5229\u5355\u6297\uff0c\u6211\u4eec\u5728\u4e73\u817a\u764c\u9886\u57df\u8fd8\u6709\u66f4\u591a\u521b\u65b0\u836f\u5728\u79ef\u6781\u5e03\u5c40\u548c\u5f00\u5c55\u4e34\u5e8a\u7814\u7a76\uff0c\u5e0c\u671b\u672a\u6765\u80fd\u7ee7\u7eed\u4e3a\u4e73\u817a\u764c\u60a3\u8005\u63d0\u4f9b\u66f4\u591a\u6cbb\u7597\u9009\u62e9\u3002\u201c<\/p>\n\n\n\n\u3010\u53c2\u8003\u6587\u732e\u3011<\/h6>\n\n\n\n
1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322\/caac.21834. Epub 2024 Apr 4. PMID: 38572751.<\/h6>\n\n\n\n
2. Https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/160-china-fact-sheets.pdf.<\/h6>\n\n\n\n
3. Dass, S.A., et al. Medicina. 2021; 57, 62.<\/h6>\n\n\n\n
4. De Laurentiis M, et al. Cancer Treat Rev. 2010;36 Suppl 3:S80-6.<\/h6>\n\n\n\n
5. Zeichner SB, et al. Breast Cancer (Auckl). 2016;10:25-36.<\/h6>\n\n\n\n
6. Zefei J, et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med 30, 249\u2013256 (2024).
<\/h6>\n\n\n\n1. <\/em>\u672c\u6750\u6599\u65e8\u5728\u4f20\u9012\u524d\u6cbf\u4fe1\u606f\uff0c\u65e0\u610f\u5411\u60a8\u505a\u4efb\u4f55\u4ea7\u54c1\u7684\u63a8\u5e7f\uff0c\u4e0d\u4f5c\u4e3a\u4e34\u5e8a\u7528\u836f\u6307\u5bfc\u3002<\/em><\/h6>\n\n\n\n
2. \u82e5\u60a8\u60f3\u4e86\u89e3\u5177\u4f53\u75be\u75c5\u8bca\u7597\u4fe1\u606f\uff0c\u8bf7\u9075\u4ece\u533b\u7597\u536b\u751f\u4e13\u4e1a\u4eba\u58eb\u7684\u610f\u89c1\u4e0e\u6307\u5bfc\u3002<\/em><\/h6>\n\n\n\n